AXSM: AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook
China-originated innovation and AI are shaping R&D and commercial operations, while AUVELITY's launch shows strong growth, especially in the Medicare 65+ segment. Conservative market assumptions support an $8 billion peak sales target, with robust pipeline progress and a clear path to profitability…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.